**Supplemental Tables 2-5: Reference Susceptibility Testing and Genomic Surveillance of *Clostridioides difficile*, United States, 2012-17**

Supplemental Table 2: Summary of vancomycin antimicrobial susceptibility testing data for *C. difficile* Emerging Infections Program 2012-2017 isolates by ribotype (n=593)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ribotype** | **Number of isolates** | **MIC50 (μg/mL)** | **MIC90 (μg/mL)** | **MIC Range (μg/mL)** | **MIC >2 μg/mLb** |
| 001\_072a | 16 | 0.5 | 1 | 0.5 to 1 | 0% |
| 002 | 79 | 0.5 | 1 | 0.5 to 1 | 0% |
| 005 | 7 | 0.5 | 1 | 0.5 to 1 | 0% |
| 014 | 65 | 0.5 | 1 | 0.5 to 1 | 0% |
| 015 | 30 | 0.5 | 1 | 0.25 to 2 | 0% |
| 017 | 2 | 0.5 | 1 | 0.5 to 1 | 0% |
| 019 | 5 | 0.5 | 0.5 | 0.5 | 0% |
| 020 | 67 | 0.5 | 1 | 0.5 to 1 | 0% |
| 027 | 137 | 2 | 2 | 0.5 to 4 | 6.6% |
| 054 | 23 | 0.5 | 0.5 | 0.5 to 1 | 0% |
| 056 | 31 | 0.5 | 1 | 0.5 to 2 | 0% |
| 076 | 13 | 0.5 | 0.5 | 0.5 | 0% |
| 078 | 18 | 0.5 | 0.5 | 0.5 to 1 | 0% |
| 106 | 100 | 0.5 | 1 | 0.5 to 1 | 0% |
| All | 593 | 0.5 | 2 | 0.25 to 4 | 1.5% |

aRT001 and RT072 are indistinguishable by high-resolution capillary gel-based PCR ribotyping.

bMIC>2 μg/mL is considered resistant by EUCAST [21] and non-wild-type according to CLSI [20].

Supplemental Table 3: Summary of metronidazole antimicrobial susceptibility testing data for *C. difficile* Emerging Infections Program 2012-2017 isolates by ribotype (n=593)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ribotype** | **Number of isolates** | **MIC50 (μg/mL)** | **MIC90 (μg/mL)** | **MIC Range (μg/mL)** | **MIC >2 μg/mLb** |
| 001\_072a | 16 | 0.5 | 1 | 0.25 to 1 | 0% |
| 002 | 79 | 0.5 | 2 | <0.125 to 2 | 0% |
| 005 | 7 | 0.5 | 1 | 0.5 to 1 | 0% |
| 014 | 65 | 0.5 | 2 | 0.25 to 4 | 4.6% |
| 015 | 30 | 0.5 | 1 | <0.125 to 1 | 0% |
| 017 | 2 | 0.5 | 0.5 | 0.5 | 0% |
| 019 | 5 | 0.25 | 0.5 | 0.25 to 0.5 | 0% |
| 020 | 67 | 0.5 | 2 | 0.25 to 4 | 4.5% |
| 027 | 137 | 1 | 2 | 0.25 to 8 | 6.6% |
| 054 | 23 | 0.5 | 1 | 0.25 to 1 | 0% |
| 056 | 31 | 0.5 | 1 | <0.125 to 1 | 0% |
| 076 | 13 | 0.5 | 1 | 0.25 to 2 | 0% |
| 078 | 18 | 0.25 | 0.5 | <0.125 to 2 | 0% |
| 106 | 100 | 0.5 | 2 | 0.25 to 4 | 1.0% |
| All | 593 | 0.5 | 2 | <0.125 to 8 | 2.7% |

aRT001 and RT072 are indistinguishable by high-resolution capillary gel-based PCR ribotyping.

bMIC>2 μg/mL is considered resistant according to EUCAST [21]. According to CLSI, all 593 isolates would be considered susceptible [20].

Supplemental Table 4: Summary of clindamycin antimicrobial susceptibility testing data for *C. difficile* Emerging Infections Program 2012-2017 isolates by ribotype (n=593)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ribotype** | **Number of isolates** | **MIC50 (μg/mL)** | **MIC90 (μg/mL)** | **MIC Range (μg/mL)** | **Isolates with *ermb* n (%)** | **Isolates with *cfrc* n (%)** |
| 001\_072a | 16 | 2 | >16 | 1 to >16 | 1 (6.3%) | 1 (6.3%) |
| 002 | 79 | 4 | 8 | <0.25 to 8 | 0 (0%) | 1 (1.3%) |
| 005 | 7 | 2 | >16 | 1 to >16 | 1 (14.3%) | 0 (0%) |
| 014 | 65 | 4 | 8 | 1 to >16 | 3 (4.6%) | 0 (0%) |
| 015 | 30 | 2 | 8 | 0.5 to >16 | 1 (3.3%) | 0 (0%) |
| 017 | 2 | 8 | 8 | 8 | 0% | 0 (0%) |
| 019 | 5 | 4 | 4 | 4 | 0% | 0 (0%) |
| 020 | 67 | 4 | 8 | <0.25 to 8 | 0% | 0 (0%) |
| 027 | 137 | >16 | >16 | <0.25 to >16 | 68 (49.6%) | 30 (21.9%) |
| 054 | 23 | 4 | 8 | <0.25 to >16 | 1 (4.3%) | 0 (0%) |
| 056 | 31 | 2 | 4 | 0.5 to >16 | 1 (3.2%) | 0 (0%) |
| 076 | 13 | 4 | 8 | 2 to 8 | 0% | 0 (0%) |
| 078 | 18 | 8 | >16 | 2 to >16 | 4 (22.2%) | 6 (33.3%) |
| 106 | 100 | 4 | 8 | <0.25 to >16 | 4 (4.0%) | 2 (2.0%) |
| All | 593 | 4 | >16 | <0.25 to >16 | 84 (14.2%) | 40 (6.7%) |

aRT001 and RT072 are indistinguishable by high-resolution capillary gel-based PCR ribotyping.

bIncludes *ermB*, *ermG*, and *ermQ*

cIncludes *cfrB*, *cfrC*, and *cfrE*

Supplemental Table 5: Summary of moxifloxacin antimicrobial susceptibility testing data for *C. difficile* Emerging Infections Program 2012-2017 isolates by ribotype (n=593)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ribotype** | **Number of isolates** | **MIC50 (μg/mL)** | **MIC90 (μg/mL)** | **MIC Range (μg/mL)** | **Isolates with GyrAmutation (T82I)**  **n (%)** | **Isolates with GyrBmutation (R447K or D426N)**  **n (%)** |
| 001\_072a | 16 | 1 | >8 | 1 to >8 | 6 (37.5%) | 0 (0%) |
| 002 | 79 | 2 | >8 | 1 to >8 | 8 (10.1%) | 2 (2.5%) |
| 005 | 7 | 1 | >8 | 1 to >8 | 1 (14.3%) | 0 (0%) |
| 014 | 65 | 2 | 2 | 1 to 8 | 0 (0%) | 2 (3.1%) |
| 015 | 30 | 1 | 2 | 1 to >8 | 1 (3.3%) | 0 (0%) |
| 017 | 2 | 1 | 2 | 1 to 2 | 0 (0%) | 0 (0%) |
| 019 | 5 | 1 | 1 | 1 | 0 (0%) | 0 (0%) |
| 020 | 67 | 2 | 2 | 1 to 2 | 0 (0%) | 0 (0%) |
| 027 | 137 | >8 | >8 | 1 to >8 | 111 (81.0%) | 7 (5.1%) |
| 054 | 23 | 1 | 2 | 1 to 2 | 0 (0%) | 0 (0%) |
| 056 | 31 | 1 | 2 | 1 to >8 | 1 (3.2%) | 0 (0%) |
| 076 | 13 | 2 | 2 | 1 to 2 | 0 (0%) | 0 (0%) |
| 078 | 18 | 1 | >8 | 1 to >8 | 2 (11.1%) | 0 (0%) |
| 106 | 100 | 2 | 2 | 1 to >8 | 4 (4.0%) | 0 (0%) |
| All | 593 | 2 | >8 | 1 to >8 | 134 (22.6%) | 11 (1.9%) |

aRT001 and RT072 are indistinguishable by high-resolution capillary gel-based PCR ribotyping.